Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Apatinib + Albumin-bound Paclitaxel in Advanced Second-line Gastric Cancer
NCT07770113Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-Free Survival at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07770113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770113.